Hakan Axelson

Prof. Hakan Axelson


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2008 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
JSJonas Sjölund
Jonas Sjölund
MJMartin Johansson
Martin Johansson
SMSugata Manna
Sugata Manna
CNCarl Norin
Carl Norin
APAlexander Pietras
Alexander Pietras
HAHakan Axelson
Hakan Axelson
Loss of the tumor suppressor gene von Hippel–Lindau (VHL) plays a key role in the oncogenesis of clear cell renal cell carcinoma (CCRCC). The loss leads to stabilization of the HIF transcription complex, which induces angiogenic and mitogenic pathways essential for tumor formation. Nonetheless, additional oncogenic events have been postulated to be required for the formation of CCRCC tumors. Here, we show that the Notch signaling cascade is constitutively active in human CCRCC cell lines independently of the VHL/HIF pathway. Blocking Notch signaling resulted in attenuation of proliferation and restrained anchorage-independent growth of CCRCC cell lines. Using siRNA targeting the different Notch receptors established that the growth-promoting effects of the Notch signaling pathway were attributable to Notch-1 and that Notch-1 knockdown was accompanied by elevated levels of the negative cell-cycle regulators p21Cip1 and/or p27Kip1. Treatment of nude mice with an inhibitor of Notch signaling potently inhibited growth of xenotransplanted CCRCC cells. Moreover, Notch-1 and the Notch ligand Jagged-1 were expressed at significantly higher levels in CCRCC tumors than in normal human renal tissue, and the growth of primary CCRCC cells was attenuated upon inhibition of Notch signaling. These findings indicate that the Notch cascade may represent a novel and therapeutically accessible pathway in CCRCC.

1 August 2017 in Cell Reports
Verified
Journal Article
Open access
DLDavid Lindgren
David Lindgren
PEPontus Eriksson
Pontus Eriksson
KKKrzysztof Krawczyk
Krzysztof Krawczyk
HNHelén Nilsson
Helén Nilsson
JHJennifer Hansson
Jennifer Hansson
HAHakan Axelson
Hakan Axelson
Comprehensive transcriptome studies of cancers often rely on corresponding normal tissue samples to serve as a transcriptional reference. In this study, we performed in-depth analyses of normal kidney tissue transcriptomes from the TCGA and demonstrate that the histological variability in cellularity, inherent in the kidney architecture, lead to considerable transcriptional differences between samples. This should be considered when comparing expression profiles of normal and cancerous kidney tissues. We exploited these differences to define renal-cell-specific gene signatures and used these as a framework to analyze renal cell carcinoma (RCC) ontogeny. Chromophobe RCCs express FOXI1-driven genes that define collecting duct intercalated cells, whereas HNF-regulated genes, specific for proximal tubule cells, are an integral part of clear cell and papillary RCC transcriptomes. These networks may be used as a framework for understanding the interplay between genomic changes in RCC subtypes and the lineage-defining regulatory machinery of their non-neoplastic counterparts.

3 August 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JSJonas Sjölund
Jonas Sjölund
ABAnna-Karin Boström
Anna-Karin Boström
DLDavid Lindgren
David Lindgren
SMSugata Manna
Sugata Manna
AMAristidis Moustakas
Aristidis Moustakas
HAHakan Axelson
Hakan Axelson
Despite recent progress, therapy for metastatic clear cell renal cell carcinoma (CCRCC) is still inadequate. Dysregulated Notch signaling in CCRCC contributes to tumor growth, but the full spectrum of downstream processes regulated by Notch in this tumor form is unknown. We show that inhibition of endogenous Notch signaling modulates TGF-β dependent gene regulation in CCRCC cells. Analysis of gene expression data representing 176 CCRCCs showed that elevated TGF-β pathway activity correlated significantly with shortened disease specific survival (log-rank test, p = 0.006) and patients with metastatic disease showed a significantly elevated TGF-β signaling activity (two-sided Student's t-test, p = 0.044). Inhibition of Notch signaling led to attenuation of both basal and TGF-β1 induced TGF-β signaling in CCRCC cells, including an extensive set of genes known to be involved in migration and invasion. Functional analyses revealed that Notch inhibition decreased the migratory and invasive capacity of CCRCC cells. An extensive cross-talk between the Notch and TGF-β signaling cascades is present in CCRCC and the functional properties of these two pathways are associated with the aggressiveness of this disease.

15 May 2011 in Molecular Cancer Research
Verified
Journal Article
Open access
PDF file
APAlexander Pietras
Alexander Pietras
KSKristoffer von Stedingk
Kristoffer von Stedingk
DLDavid Lindgren
David Lindgren
SPSven Påhlman
Sven Påhlman
HAHakan Axelson
Hakan Axelson
Several studies have revealed links between hypoxia and activation of Notch in solid tumors. While most reports have focused on intracellular domain of the Notch1 receptor (icN1) stabilization by direct interaction with HIF proteins, little attention has been given to Notch ligand regulation during hypoxia. Here we show that the Notch ligand JAG2 is transcriptionally activated by hypoxia in a HIF-1α dependent manner. Hypoxic JAG2 induction resulted in elevated Notch activity in tumor cells, as was measured by increased icN1 levels and induction of the Notch target gene HEY1. In primary tumor material, JAG2 expression correlated with vascular development and angiogenesis gene signatures. In line with this, coculture experiments of endothelial cells with hypoxic breast cancer cells displayed a reduction in number of capillary-like tubes formed upon JAG2 siRNA treatment of the breast cancer cells. Together these results suggest that a hypoxic induction of JAG2 in tumor cells mediates a hypoxia-regulated cross-talk between tumor and endothelial cells. Mol Cancer Res; 9(5); 626–36. ©2011 AACR.

5 July 2021 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
SWShan Wang
Shan Wang
EEEmelie Englund
Emelie Englund
PKPontus Kjellman
Pontus Kjellman
ZLZhen Li
Zhen Li
JAJohannes Kumra Ahnlide
Johannes Kumra Ahnlide
CMChris D. Madsen
Chris D. Madsen

9 February 2024 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
LSLourdes Sainero-Alcolado
Lourdes Sainero-Alcolado
EGElisa Garde-Lapido
Elisa Garde-Lapido
MSMarteinn Thor Snaebjörnsson
Marteinn Thor Snaebjörnsson
SSSarah Schoch
Sarah Schoch
ISIrene Stevens
Irene Stevens
MAMarie Arsenian-Henriksson
Marie Arsenian-Henriksson
Metabolic reprogramming is critical during clear cell renal cell carcinoma (ccRCC) tumorigenesis, manifested by accumulation of lipid droplets (LDs), organelles that have emerged as new hallmarks of cancer. Yet, regulation of their biogenesis is still poorly understood. Here, we demonstrate that MYC inhibition in ccRCC cells lacking the von Hippel Lindau ( VHL ) gene leads to increased triglyceride content potentiating LD formation in a glutamine-dependent manner. Importantly, the concurrent inhibition of MYC signaling and glutamine metabolism prevented LD accumulation and reduced tumor burden in vivo. Furthermore, we identified the hypoxia-inducible lipid droplet–associated protein (HILPDA) as the key driver for induction of MYC-driven LD accumulation and demonstrated that conversely, proliferation, LD formation, and tumor growth are impaired upon its downregulation. Finally, analysis of ccRCC tissue as well as healthy renal control samples postulated HILPDA as a specific ccRCC biomarker. Together, these results provide an attractive approach for development of alternative therapeutic interventions for the treatment of this type of renal cancer.